Who is suitable for seputinib/serpatinib?

Selpercatinib is a highly selective RET inhibitor that plays an important role in the field of molecular targeted therapy. It mainly targets tumors related to RET gene alterations, including RET fusion-positive non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), and some RET fusion-positive thyroid cancers. With the development of medicine, the importance of genetic testing is increasingly emphasized clinically. Seputinib is a typical "gene drive" targeted drug, which is suitable for people closely related to RET gene mutations or fusions.

For patients with advanced or metastatic RET fusion-positive non-small cell lung cancer whose disease has not been effectively controlled after conventional chemotherapy or immunotherapy, seputinib is usually recommended as the priority treatment option. Clinical studies show that such patients often have better remission rates and a chance of extending survival time after taking medication. At the same time, some untreated RET-positive lung cancer patients can also use seputinib during the initial treatment phase to improve the tumor control rate and reduce the risk of disease progression.

In the field of thyroid cancer, seputinib also shows unique advantages. Especially for patients with sporadic or hereditary medullary thyroid cancer who are positive for RET mutations, treatment methods have been limited in the past. However, septetinib can precisely act on the RET pathway and improve the disease control rate. In addition, seputinib can also become a new option for patients with RET fusion-positive papillary thyroid cancer who have failed iodine-131 treatment or multiple lines of treatment.

It is worth mentioning that seputinib not only emphasizes efficacy, but also takes into account tolerability. Compared with traditional multi-target tyrosine kinase inhibitors (such as cabozantinib and vandetanib), its side effects are more selective and reduce the impact on non-target pathways, thereby bringing better safety and quality of life. This is particularly critical for some cancer patients who require long-term oral targeted drugs.

Reference:https://en.wikipedia.org/wiki/Selpercatinib